436 results
Keyword Simvastatin Remove keyword
-
List item
Press release: European Medicines Agency confirms recommendation to suspend Tredaptive, Pelzont and Trevaclyn
CHMP, Last updated: 18/01/2013Patients were treated with simvastatin 40 mg or simvastatin 40 mg plus ezetimibe 10 mg … Patients were treated with simvastatin 40 mg or simvastatin 40 mg plus ezetimibe 10 mg … -
List item
National expert: Nuno Miguel Elvas Neves Silva, National Authority Of Medicines And Health Products (updated)
- Declaration of interests - 43.63 KB | PDF
- Curriculum Vitae - 47.73 KB | PDF
wi Past 02-01- 2020 20-02- 2021 BlueClinical Phase I simvastatin (EudraCT no. 2019- 004159-36) Hyperlipidemia Past 01-04- 2021 30-06- 2022 BlueClinical … -
List item
National expert: Francois Houyez, European Medicines Agency (updated)
- Declaration of interests - 44.66 KB | PDF
- Curriculum Vitae - 35.57 KB | PDF
non-active-champion Current 01-09- 2022 simvastatin pancreatic cancer non-active-champion Current 01-09- 2022 tazarotene … -
List item
National expert: Joao Jose Sousa, National Authority Of Medicines And Health Products (updated)
- Declaration of interests - 39.41 KB | PDF
- Curriculum Vitae - 47.84 KB | PDF
Books 1. Simvastatin delivery: Challenges and … Sousa, Alberto Pais (Eds), Simvastatin delivery: Challenges and … -
List item
Human medicine European public assessment report (EPAR): Pravafenix (updated)
fenofibrate, Pravastatin, Dyslipidemias
Date of authorisation: 14/04/2011, Revision: 8, Authorised, Last updated: 28/11/2023 -
List item
Human medicine European public assessment report (EPAR): Leflunomide medac (updated)
leflunomide, Arthritis, Rheumatoid
Date of authorisation: 27/07/2010,, Revision: 19, Authorised, Last updated: 04/12/2023
-
List item
Human medicine European public assessment report (EPAR): Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan (updated)
efavirenz, emtricitabine, tenofovir disoproxil maleate, HIV Infections
Date of authorisation: 05/09/2017,, Revision: 16, Authorised, Last updated: 20/11/2023
-
List item
Human medicine European public assessment report (EPAR): Posaconazole AHCL (updated)
posaconazole, Mycoses
Date of authorisation: 25/07/2019,, Revision: 6, Authorised, Last updated: 20/11/2023
-
List item
Human medicine European public assessment report (EPAR): Zokinvy (updated)
Lonafarnib, Progeria; Laminopathies
Date of authorisation: 18/07/2022,,
,
, Revision: 2, Authorised, Last updated: 09/11/2023
-
List item
Human medicine European public assessment report (EPAR): Rezolsta (updated)
darunavir, cobicistat, HIV Infections
Date of authorisation: 19/11/2014, Revision: 16, Authorised, Last updated: 21/11/2023 -
List item
Human medicine European public assessment report (EPAR): Norvir
ritonavir, HIV Infections
Date of authorisation: 25/08/1996, Revision: 69, Authorised, Last updated: 25/10/2023 -
List item
Human medicine European public assessment report (EPAR): Livmarli (updated)
Maralixibat chloride, Alagille Syndrome
Date of authorisation: 09/12/2022,,
,
, Revision: 3, Authorised, Last updated: 13/11/2023
-
List item
Human medicine European public assessment report (EPAR): Tagrisso (updated)
osimertinib mesilate, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 01/02/2016,, Revision: 19, Authorised, Last updated: 20/11/2023
-
List item
Human medicine European public assessment report (EPAR): Kaletra
lopinavir, ritonavir, HIV Infections
Date of authorisation: 19/03/2001, Revision: 61, Authorised, Last updated: 19/10/2023 -
List item
Human medicine European public assessment report (EPAR): Lunsumio (updated)
mosunetuzumab, Lymphoma, Follicular
Date of authorisation: 03/06/2022,,
,
, Revision: 2, Authorised, Last updated: 09/11/2023
-
List item
Human medicine European public assessment report (EPAR): Sprycel
dasatinib, Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Date of authorisation: 20/11/2006, Revision: 41, Authorised, Last updated: 30/10/2023 -
List item
Human medicine European public assessment report (EPAR): Kisqali (updated)
ribociclib succinate, Breast Neoplasms
Date of authorisation: 22/08/2017, Revision: 14, Authorised, Last updated: 20/11/2023 -
List item
Human medicine European public assessment report (EPAR): Glivec (updated)
imatinib, Precursor Cell Lymphoblastic Leukemia-Lymphoma; Gastrointestinal Stromal Tumors; Dermatofibrosarcoma; Myelodysplastic-Myeloproliferative Diseases; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Hypereosinophilic Syndrome
Date of authorisation: 07/11/2001,, Revision: 46, Authorised, Last updated: 20/11/2023
-
List item
Human medicine European public assessment report (EPAR): Steglujan
ertugliflozin l-pyroglutamic acid, sitagliptin phosphate monohydrate, Diabetes Mellitus, Type 2
Date of authorisation: 23/03/2018, Revision: 11, Authorised, Last updated: 19/09/2023 -
List item
Human medicine European public assessment report (EPAR): Xelevia (updated)
sitagliptin, Diabetes Mellitus, Type 2
Date of authorisation: 21/03/2007, Revision: 39, Authorised, Last updated: 30/11/2023 -
List item
Human medicine European public assessment report (EPAR): Zejula (updated)
Niraparib (tosilate monohydrate), Fallopian Tube Neoplasms; Peritoneal Neoplasms; Ovarian Neoplasms
Date of authorisation: 16/11/2017,, Revision: 22, Authorised, Last updated: 07/11/2023
-
List item
Human medicine European public assessment report (EPAR): Glyxambi
empagliflozin, linagliptin, Diabetes Mellitus, Type 2
Date of authorisation: 11/11/2016, Revision: 16, Authorised, Last updated: 27/09/2023 -
List item
Human medicine European public assessment report (EPAR): Exforge HCT
valsartan, hydrochlorothiazide, Amlodipine besilate, Hypertension
Date of authorisation: 15/10/2009, Revision: 24, Authorised, Last updated: 29/09/2023 -
List item
Human medicine European public assessment report (EPAR): Dafiro HCT
valsartan, hydrochlorothiazide, Amlodipine besilate, Hypertension
Date of authorisation: 03/11/2009, Revision: 26, Authorised, Last updated: 27/09/2023 -
List item
Human medicine European public assessment report (EPAR): Copalia HCT
amlodipine, valsartan, hydrochlorothiazide, Hypertension
Date of authorisation: 03/11/2009, Revision: 24, Authorised, Last updated: 27/09/2023